These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25933245)

  • 1. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
    Liu J; Liu B; Guo G; Jing Y; Zhao G
    Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
    Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
    Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
    Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
    J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
    Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
    J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
    Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
    Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
    Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
    Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
    Li H; Ban F; Dalal K; Leblanc E; Frewin K; Ma D; Adomat H; Rennie PS; Cherkasov A
    J Med Chem; 2014 Aug; 57(15):6458-67. PubMed ID: 25062331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
    Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
    Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
    Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
    Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
    Xu X; Ge R; Li L; Wang J; Lu X; Xue S; Chen X; Li Z; Bian J
    Eur J Med Chem; 2018 Jan; 143():1325-1344. PubMed ID: 29117897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E; Zauhar RJ
    J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel androgen receptor antagonists via molecular modeling.
    Zhao C; Choi YH; Khadka DB; Jin Y; Lee KY; Cho WJ
    Bioorg Med Chem; 2016 Feb; 24(4):789-801. PubMed ID: 26780832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
    Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
    Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Anti-Resistance AR Antagonists Guided by Funnel Metadynamics Simulation.
    Chen H; Zhou Y; Wang X; Chai X; Wang Z; Wang E; Xu L; Hou T; Li D; Duan M
    Adv Sci (Weinh); 2024 May; 11(19):e2309261. PubMed ID: 38481034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel 5-methyl-1H-pyrazole derivatives as potential antiprostate cancer agents: Design, synthesis, molecular modeling, and biological evaluation.
    Zhang D; Asnake S; Zhang J; Olsson PE; Zhao G
    Chem Biol Drug Des; 2018 Jun; 91(6):1113-1124. PubMed ID: 29388326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer.
    Zhang W; Fan Y; Zhang Y; Feng Y; Luo Y; Zhou X; Chen Z; Wang C; Lu T; Tang F; Chen Y; Li H; Jiao Y
    Bioorg Chem; 2024 Jul; 148():107433. PubMed ID: 38754311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
    Yan J; Xie B; Capodice JL; Katz AE
    Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.